Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Veto Threat Centers On Opioid Language In Approps Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

There’s a lot the White House doesn’t like in the House agriculture spending bill, including concern about the potential precedent of the provision linking FDA funding to release of guidance.

You may also be interested in...

Compassionate Use Study Added To House Approps Orders

House Appropriations Committee wants to better understand issues with denied expanded access requests and requests Government Accountability Office study of FDA efforts in funding bill.

Shutdown Week Two: Could Sponsors Find A More Focused FDA?

User-fee supported employees continue to work on pending reviews, and the lack of distractions from other tasks may help sponsors as the shutdown continues.

FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling

Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts